6 / 35
Page 68
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Strategies for the detection, treatment and management of sepsis
Maannashon Prabaharan
King’s College London, UK
S
epsis is caused by the host’s over-response to an infection, which leads to organ failure. This affects many areas
of the body, including the cardiovascular, renal, GI and pulmonary systems. Sepsis has high mortality rates, with
survivors being affected by complications, including cognitive decline and increased cardiovascular events.
Current methods for diagnosing sepsis include the use of physical biomarkers such as heart rate (HR), and serological
biomarkers such as C-Reactive Protein (CRP) and Procalcitonin (PCT). Clinical trials were found through literature
searches using the PubMed and Ovid databases. The cumulative evidence suggests that other serological biomarkers
such as presepsin, Pentraxin-3 (PTX3) and micro-RNA have potential for future clinical use. Heart rate variability
(HRV) is a newer physical biomarker that has good evidence for diagnosing sepsis patients.
The Surviving Sepsis Campaign has annual updates on guidelines for clinicians in treating sepsis. The latest
guidelines have included the empirical use of broad-spectrum antimicrobials to be given immediately, as part of a
‘1-hour bundle’, which does have disadvantages. The growing evidence suggests of a trend in increasing antimicrobial
resistance, therefore, new alternatives should be found. This text has evidence for alternative methods, such as the use
of antimicrobial stewardship (responsible use of antibiotics) and bacteriophages (viruses which infect and destroy
bacteria).
Recent innovations in technology over the past decade have been integrated into clinical practice, and there is great
hope for the near future with new research into predictive algorithms and consumer technology in treating patients.
This review aims to summarise the current developments that have occurred in the diagnosis, treatment and
management of septic patients. This review also aims to show the reader what future developments hold for
improving the quality of sepsis management.
Recent Publications:
1.
Koch, A., Nilsen, R., Eriksen, H., Cox, R. and Harthug, S. (2015). Mortality related to hospital-associated
infections in a tertiary hospital; repeated cross-sectional studies between 2004-2011. Antimicrobial Resistance
and Infection Control, 4(57).
2.
Jurač, K., Nabergoj, D. and Podgornik, A. (2018). Bacteriophage production processes. Applied Microbiology
and Biotechnology. In press.
3.
Wu, X., Yang, J., Yu, L. and Long, D. (2018). Plasma miRNA-223 correlates with risk, inflammatory markers
as well as prognosis in sepsis patients. Medicine, 97(27), p.e11352
4.
Liu, Y., Yu, M., Shou, S. and Chai, Y. (2017). Sepsis-Induced Cardiomyopathy: Mechanisms and Treatments.
Frontiers in Immunology, 8, pp.1-8.
Biography
Maannashon Prabaharan is an intercalating student who has interests in Pharmacology, and its uses in clinical practice. This paper vocalizes his opinions about
the current clinical scenario regarding sepsis (Levy et al. 2018), and potential future changes that could be implemented in all aspects of clinical care.
Maannashon Prabaharan, Clin Pharmacol Biopharm, Volume 08